+Compare
ATOS
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
101.46M

ATOS Atossa Therapeutics Forecast, Technical & Fundamental Analysis

a manufacturer of products for breast cancer

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for ATOS with price predictions
07:00 PM EST Nov 27, 2023

ATOS in +5.33% Uptrend, rising for three consecutive days on November 27, 2023

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ATOS advanced for three days, in of 222 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 20, 2023. You may want to consider a long position or call options on ATOS as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ATOS just turned positive on November 16, 2023. Looking at past instances where ATOS's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

ATOS moved above its 50-day moving average on November 20, 2023 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ATOS crossed bullishly above the 50-day moving average on November 27, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ATOS moved out of overbought territory on November 28, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATOS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ATOS broke above its upper Bollinger Band on November 21, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ATOS entered a downward trend on November 06, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.033) is normal, around the industry mean (20.463). P/E Ratio (0.000) is within average values for comparable stocks, (137.276). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.954). Dividend Yield (0.000) settles around the average of (0.036) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (329.780).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ATOS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATOS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was 33%, and the average quarterly price growth was 8%. AWKNF experienced the highest price growth at 165%, while AXLA experienced the biggest fall at -76%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -50%. For the same stocks of the Industry, the average monthly volume growth was -53% and the average quarterly volume growth was -26%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 63
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: -5 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

ATOS is expected to report earnings to rise 46.60% to -7 cents per share on March 28

Atossa Therapeutics ATOS Stock Earnings Reports
Q4'23
Est.
$-0.07
Q3'23
Beat
by $0.02
Q2'23
Missed
by $0.02
Q1'23
Beat
by $0.01
Q4'22
Est.
$-0.06
The last earnings report on November 13 showed earnings per share of -5 cents, beating the estimate of -6 cents. With 272.73K shares outstanding, the current market capitalization sits at 101.46M.
A.I. Advisor
published General Information

General Information

a manufacturer of products for breast cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
107 Spring Street
Phone
+1 206 588-0256
Employees
11
Web
https://www.atossatherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MPLSX9.630.03
+0.31%
MassMutual Strat Emerg Mkts Adm
FSANX14.200.04
+0.28%
Fidelity Asset Manager® 60%
SGIDX29.670.06
+0.20%
Steward Global Equity Income Fund A
MSCUX10.61-0.01
-0.09%
Morgan Stanley American Resilience A
LMCYX29.73-0.21
-0.70%
Lord Abbett Mid Cap Stock I

ATOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATOS has been loosely correlated with SRNEQ. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ATOS jumps, then SRNEQ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATOS
1D Price
Change %
ATOS100%
-3.94%
SRNEQ - ATOS
47%
Loosely correlated
+11.96%
MDGL - ATOS
45%
Loosely correlated
-3.22%
AXON - ATOS
42%
Loosely correlated
-0.48%
AVRO - ATOS
37%
Loosely correlated
-0.80%
GOSS - ATOS
36%
Loosely correlated
-7.41%
More

Groups containing ATOS

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATOS
1D Price
Change %
ATOS100%
-3.94%
medical research
(undefined stocks)
15%
Poorly correlated
-0.40%
medical service
(undefined stocks)
14%
Poorly correlated
-0.40%
cancer
(undefined stocks)
14%
Poorly correlated
-0.43%